What Are the Determinants of Explicit and Implicit Motor Imagery Ability in Stroke Patients?

December 24, 2019 updated by: Esma Nur KOLBAŞI, Istanbul Medeniyet University

What Are the Determinants of Explicit and Implicit Motor Imagery Ability in Stroke Patients?: A Controlled Study

Motor imagery (MI) might be described as a dynamic process in which an individual mentally stimulates an action without any overt movement. After stroke, motor imagery ability is impaired and also due to structure of MI, not every stroke patients is able to perform MI. Therefore, the aim of the study is a) to compare both explicit and implicit motor imagery ability (MIA) between patients with stroke and healthy subjects, b) to examine predictive effects of clinical characteristics for MIA after stroke.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

77

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Istanbul, Turkey, 34394
        • Bakırköy Dr. Sadi Konuk Training and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Stroke patients and age, sex, education matched healthy volunteers who meet the inclusion criteria

Description

Inclusion Criteria:

  • Being between the ages of 18-80,
  • Having a unilateral stroke for the first time and 0-6 months since stroke onset
  • 24 points and above in Mini Mental State Examination (MMDM)
  • Not having a disease that may interfere with the study such as cardiac diseases, orthopedic conditions,etc.

Exclusion Criteria:

  • Multiple strokes
  • Sever cognitive dysfunction (<24 points in MMDM)
  • Unilateral neglect
  • Upper extremity pain that interferes with the study or aggravated with movement
  • Visual problems, aphasia or another sequel that might limit the assessment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Healthy Group
Stroke Group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Movement Imagery Questionnaire-3 (MIQ-3)
Time Frame: 15 min
MIQ-3 evaluates an individual's motor imagery ability in 3 subscales: 1. internal imagery, 2. external imagery, 3. kinesthetic imagery. Each of these scales ranges from 1 to 7 where 1 indicates very hard to see/feel (image) and 7 indicates very easy to see/feel. 12 items are included in the MIQ-3 and every item is scored according to the scales. The higher the score in subscales, the better the results are.
15 min
Chaotic Motor Imagery Assessment- Hand Rotation
Time Frame: 20 min
Hand Rotation is the first component of Chaotic Motor Imagery Assessment. In this measure, 96 drawings of each hand (left and right) from 4 different plane and at 12 different angle are presented to the individuals and then, it is asked to decide whether it is left or right hand. Total test time, total accuracy, total wrong answers, right accuracy, left accuracy, impaired hand and non-impaired hand accuracy is recorded as outcome scores.
20 min
Box and Block Test
Time Frame: 5 min
Box and Block Test is used to calculate mental chronometry (MC) ratio. During the test, patients are asked to carry 15 blocks first physically and then mentally from one box to another. As outcome scores, the time required to carry 15 blocks physically (MET) and mentally (MIT) are recorded. Then MC ratio is calculated with the formula: (MET-MIT)/ MET.
5 min
Fugl-Meyer Assessment- Upper Extremity
Time Frame: 10 min

Upper extremity part of Fugl Meyer Assessment (FMAUE) is used to evaluate patients' motor impairment level. Total motor and sensory scores are recorded. Then, patients are divided into 4 different categories according to their motor impairment level:

  1. 23-31 points: poor upper extremity function,
  2. 32-47 points: limited function,
  3. 48-52 points: notable function, 4.53-66 points: full function.
10 min

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Motor Activity Log-28
Time Frame: 5 min
Turkish version of MAL-28 was used to assess how much (amount of use scale) and how well (how well scale) the patients used their upper extremity in daily life after stroke. These 2 different scales are calculated separately with range of 0-5 points.The higher the points are, the better the patients' situation.
5 min

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 17, 2018

Primary Completion (Actual)

September 30, 2018

Study Completion (Actual)

September 30, 2018

Study Registration Dates

First Submitted

August 14, 2018

First Submitted That Met QC Criteria

August 14, 2018

First Posted (Actual)

August 17, 2018

Study Record Updates

Last Update Posted (Actual)

December 27, 2019

Last Update Submitted That Met QC Criteria

December 24, 2019

Last Verified

December 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

3
Subscribe